Compare BioNano Genomics Inc (BNGO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Under Armour Inc Class A — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Under Armour Inc Class A trades at $5.15 (market cap $2.26B). The key difference: Under Armour Inc Class A is far larger — about 165.4× BioNano Genomics Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | UA | |
|---|---|---|
Market Cap | $13.66M | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $7.88 |
52-Week Low | $1.06 | $3.96 |
Enterprise Value | $16.26M | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Under Armour (UA) trades at $5.14, down 9.43% amid bearish technical signals and negative profitability metrics. The company reported Q1 2026 revenue of $1.1 billion, missing expectations, and lowered its fiscal 2027 revenue outlook due to soft consumer demand in North America and Asia-Pacific. Despite beating EPS estimates in two of the last three quarters, negative net income margin of -9.99% and declining revenue trends highlight ongoing challenges.
The stock faces significant headwinds from deteriorating fundamentals and negative cash flow, though analyst consensus remains cautiously optimistic with 38.8% buy ratings. Key risks include continued revenue declines, competitive pressure, and execution challenges in the turnaround strategy. The current valuation at 0.45 P/S offers potential value if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
